Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

Journal Articles

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Blood (2022) 140 (Supplement 1): 771–773.

https://doi.org/10.1182/blood-2022-165917

Published: 2022

Journal Articles

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

Sarah Gillessen, MD, Annette Plütschow, Michael Fuchs, MD, Jana Markova, MD, Richard Greil, MD, Max S. Topp, MD, Julia Meissner, MD, Josée M Zijlstra, MD PhD, Dennis A. Eichenauer, Volker Diehl, MD, Peter Borchmann, MD PhD, Andreas Engert, MD, Bastian von Tresckow, MD

Blood (2019) 134 (Supplement_1): 129.

https://doi.org/10.1182/blood-2019-125249

Published: 2019

Journal Articles

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe, MD, Hans Eich, MD, Christian Baues, MD, Richard Greil, MD, Stephanie Sasse, MD, Josée M Zijlstra, MD, Andreas Lohri, MD, Andreas Rosenwald, Bastian von Tresckow, MD, Volker Diehl, MD, Georg Kuhnert, Markus Dietlein, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2018) 132 (Supplement 1): 925.

https://doi.org/10.1182/blood-2018-99-114519

Published: 2018

Journal Articles

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

Dennis A. Eichenauer, Annette Plütschow, Lena Schröder, Michael Fuchs, Boris Böll, Bastian von Tresckow, Volker Diehl, Peter Borchmann, Andreas Engert

Blood (2018) 132 (14): 1519–1525.

https://doi.org/10.1182/blood-2018-02-836437

Published: 2018

Journal Articles

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Lena Schroeder, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2016) 128 (22): 922.

https://doi.org/10.1182/blood.V128.22.922.922

Published: 2016

Journal Articles

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Stefanie Kreissl, MD, Bastian von Tresckow, MD, Helen Goergen, PhD, Heinz Haverkamp, Stephanie Sasse, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2016) 128 (22): 923.

https://doi.org/10.1182/blood.V128.22.923.923

Published: 2016

Journal Articles

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann

Blood (2016) 127 (18): 2189–2192.

https://doi.org/10.1182/blood-2015-11-681064

Published: 2016

Journal Articles

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Pluetschow, Heinz Haverkamp, Stefanie Kreissl, MD, Michael Fuchs, Martin Soekler, Johannes C. Hellmuth, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, Carsten Kobe, Volker Diehl, MD, Andreas Engert

Blood (2015) 126 (23): 580.

https://doi.org/10.1182/blood.V126.23.580.580

Published: 2015

Journal Articles

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Stefanie Kreissl, MD, Helen Goergen, Bastian von Tresckow, MD, Karolin Behringer, MD, Jana Markova, MD, Andreas Lohri, MD, Julia Meissner, MD, Josée M Zijlstra, MD, Richard Greil, MD, Max S. Topp, MD, Martin Sökler, MD, Hartmut Döhner, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2015) 126 (23): 3941.

https://doi.org/10.1182/blood.V126.23.3941.3941

Published: 2015

Journal Articles

Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years

Stefanie Kreissl, MD, Horst Mueller, PhD, Axel Mayer, Karolin Behringer, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 854.

https://doi.org/10.1182/blood.V124.21.854.854

Published: 2014

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Annette Pluetschow, Michael Fuchs, MD, Karolin Behringer, MD, Boris Böll, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2014) 124 (21): 3058.

https://doi.org/10.1182/blood.V124.21.3058.3058

Published: 2014

Journal Articles

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Boris Böll, MD, Karolin Behringer, MD, Helen Görgen, Paul Bröckelmann, MD, Bastian von Tresckow, MD, Dennis A. Eichenauer, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2014) 124 (21): 3062.

https://doi.org/10.1182/blood.V124.21.3062.3062

Published: 2014

Journal Articles

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Dennis A. Eichenauer, Indra Thielen, Heinz Haverkamp, Jeremy Franklin, Karolin Behringer, Teresa Halbsguth, Beate Klimm, Volker Diehl, Stephanie Sasse, Achim Rothe, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert

Blood (2014) 123 (11): 1658–1664.

https://doi.org/10.1182/blood-2013-07-512657

Published: 2014

Includes: Supplemental data

Journal Articles

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Peter Borchmann, MD, Dennis A. Eichenauer, MD, Annette Plütschow, PhD, Stefanie Kreissl, MD, Michael Fuchs, MD, Martin Soekler, MD, Nicole Engel, MD, Julia Meissner, MD, Stephan Mathas, Karolin Behringer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4344.

https://doi.org/10.1182/blood.V122.21.4344.4344

Published: 2013

Journal Articles

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Blood (2012) 120 (21): 2636.

https://doi.org/10.1182/blood.V120.21.2636.2636

Published: 2012

Journal Articles

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Andreas Engert, MD, Carsten Kobe, MD, Heinz Haverkamp, Georg Kuhnert, Jana Markova, MD, Andreas Lohri, MD, Susanne Klutmann, MD, Holger Amthauer, MD, Volker Diehl, MD, Peter Borchmann, MD, Markus Dietlein, MD

Blood (2012) 120 (21): 3684.

https://doi.org/10.1182/blood.V120.21.3684.3684

Published: 2012

Journal Articles

Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors

Beate Klimm, MD, Helen Goergen, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Hans Theodor Eich, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2012) 120 (21): 54.

https://doi.org/10.1182/blood.V120.21.54.54

Published: 2012

Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Blood (2012) 120 (21): 548.

https://doi.org/10.1182/blood.V120.21.548.548

Published: 2012

NARROW

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)

Beacoppescalated Followed By Radiotherapy of Initial Bulk or Residual Disease in Advanced Stage Hodgkin Lymphoma: Long-Term Follow up of the HD9 and HD12 Trials of the German Hodgkin Study Group

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Targeted Beacopp Variants in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Final Analysis of a Randomized Phase II Study

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Fatigue in Hodgkin Lymphoma Patients: Longitudinal Evaluation and Curve Types up to 5 Years

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Treatment of Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): An Analysis from the German Hodgkin Study Group (GHSG)

Doxorubicin, Vinblastine and Dacarbazine with or without Bleomycin for Older Patients with Early Stage Favorable Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 Trials

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Targeted Beacopp Variants In Patients With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma: Interim Results Of a Randomized Phase II Study

Gonadal Function in Survivors After Hodgkin Lymphoma (HL) Treatment within the German Hodgkin Study Group (GHSG) HD13–15 Trials.

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only